MTM Drug Therapy Monitoring & Clinical Decision-Making 5

Question 1

A patient with bipolar disorder on valproic acid has a level of 65 mcg/mL (therapeutic 50-125 mcg/mL) but still has breakthrough mania. What is the most appropriate clinical action?

Accepted Answer

Increase valproic acid dose targeting 100-125 mcg/mL

Answer

Valproic acid level is suboptimal within the therapeutic range; increasing the dose to target the higher end (100-125 mcg/mL) is the appropriate first step before adding a second agent.

Question 2

Which assessment finding would prompt a pharmacist to recommend DECREASING the frequency of blood pressure monitoring from weekly to monthly in a stable hypertensive patient?

Accepted Answer

Three consecutive readings at goal (130/80 mmHg) on stable therapy over 3 months

Answer

Consistent at-goal blood pressure readings over multiple months on stable therapy indicate the patient is well-controlled, supporting a reduced monitoring frequency.

Question 3

A patient with HIV on a protease inhibitor-based regimen is started on inhaled fluticasone for asthma. Which adverse outcome should the pharmacist monitor for most urgently?

Accepted Answer

Adrenal suppression and Cushing syndrome

Answer

Ritonavir (a common protease inhibitor booster) strongly inhibits CYP3A4, markedly increasing fluticasone systemic exposure and risking iatrogenic Cushing syndrome and adrenal suppression.

Question 4

When monitoring a patient on clozapine, which laboratory value requires the MOST stringent surveillance schedule due to a potentially fatal adverse effect?

Accepted Answer

Absolute neutrophil count (ANC) per REMS protocol

Answer

Clozapine's REMS program mandates ANC monitoring to detect clozapine-induced agranulocytosis, a potentially fatal adverse effect requiring immediate drug discontinuation if ANC falls below threshold.

Question 5

A 78-year-old patient on warfarin for atrial fibrillation has a CHA₂DS₂-VASc score of 5 and HAS-BLED score of 4. What is the most appropriate clinical recommendation?

Accepted Answer

Continue warfarin with frequent INR monitoring and address modifiable bleeding risk factors

Answer

A high HAS-BLED score should prompt correction of modifiable bleeding risks (e.g., uncontrolled hypertension, interacting drugs), not anticoagulation discontinuation, as stroke risk remains substantially higher.

(MTM) Medication Therapy Management Certification for Pharmacists Practice Test

(MTM) Medication Therapy Management Certification for Pharmacists Practice Test

MTM Drug Therapy Monitoring & Clinical Decision-Making 5